Details of the Drug Reposition

General Information of This Drug (ID: DMH7W9X)

• Drug Name: SNDX-275 (DMH7W9X)
• Synonyms: Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

1 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Breast cancer	DIS7DPX1	2C60-2C65	Phase 3	[1]

4 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Colorectal cancer	DISNH7P9	2B91.Z	Phase 2	[2]
Non-small-cell lung cancer	DIS5Y6R9	2C25.Y	Phase 2	[2]
Melanoma	DIS1RRCY	2C30	Phase 2	[2]
Ovarian cancer	DISZJHAP	2C73	Phase 2	[2]

References

• [1] ClinicalTrials.gov (NCT03538171) Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)